Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.

Annals of neurology - 1 Jan 2011

Corvol Jean-Christophe, Bonnet Cécilia, Charbonnier-Beaupel Fanny, Bonnet Anne-Marie, Fiévet Marie-Hélène, Bellanger Agnès, Roze Emmanuel, Meliksetyan Gayané, Ben Djebara Mouna, Hartmann Andreas, Lacomblez Lucette, Vrignaud Cédric, Zahr Noël, Agid Yves, Costentin Jean, Hulot Jean-Sébastien, Vidailhet Marie

Abstract excerpt

OBJECTIVE: In Parkinson disease (PD), the selective C-O-methyltransferase (COMT) inhibitor entacapone prolongs the effect of levodopa on motor symptoms (ON time) by increasing its bioavailability. The COMT Val158Met polymorphism is equally distributed in PD patients and modulates COMT activity, which can be high (Val/Val, COMT(HH) ), intermediate (Val/Met, COMT(HL) ), or low (Met/Met, COMT(LL) ). The objective of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiparkinson Agents
Share to Biological Availability

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Catechols

Share to Cross-Over Studies

Share to Double-Blind Method

Share to Levodopa

Share to Methionine

Share to Nitriles

Source

Identifiers

PMID: 21280081
DOI: 10.1002/ana.22155

Genes

COMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.PMID 21280081Read ↗

The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism.Semantic proximity Read ↗

COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease.Semantic proximity Read ↗

Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease.Semantic proximity Read ↗

Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism.Semantic proximity Read ↗

Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.Semantic proximity Read ↗

Association of Catechol-O-Methyltransferase Gene rs4680 Polymorphism and Levodopa Induced Dyskinesia in Parkinson's Disease: A Meta-Analysis and Systematic Review.Semantic proximity Read ↗

Catechol-O-methyltransferase and Parkinson's disease.Semantic proximity Read ↗

Role of Catechol-O-Methyltransferase (COMT)-Dependent Processes in Parkinson’s Disease and L-DOPA TreatmentSemantic proximity Read ↗

Association of catechol-o-methyltransferase polymorphism (Val108/158Met) with Parkinson's disease: a meta-analysis.Semantic proximity Read ↗

The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complicationsSemantic proximity Read ↗

A Systematic Review of Parkinson's Disease Pharmacogenomics: Is There Time for Translation into the Clinics?Semantic proximity Read ↗

Association of COMT Val158Met polymorphism with wearing-off susceptibility in Parkinson's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.